Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologist who treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Articles with lock require a subscription to GLG News | Request a free trial
July 8, 2008
What ever happens I can assure you the Doctors will be f........
Analysis of: Clash on Preventing Cut to Doctor Payments | online.wsj.com
Author: GLG Expert Contributor
11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?
July 7, 2008
Cost vs Efficacy: A conundrum for insurers, physicians and patients.
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.
July 3, 2008
Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Expert Contributor
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
July 3, 2008
Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: GLG Expert Contributor
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
June 30, 2008
GSK's Lapatanib: ways from competing with Herceptin
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In a recent JCO article, Laptanib showed clinical efficacy and acceptable safety in a non-randomized trial involving newly diagnosed patients with advanced oe metastatic breast cancer. Larger trials are needed to confirm efficacy and explore if it is more potent than Genentech's Herceptin. For now,...
June 30, 2008
Avastin for front-line treatment of metastatic breast cancer: Not a big market
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor
Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...
June 30, 2008
The heck with the impact on Roche. How about the patients??
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
June 30, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
June 27, 2008
The other shoe falls II: Amgen and J & J will not be happy.
Analysis of: Europe Backs Anemia-Drug Warnings | online.wsj.com
Author: GLG Expert Contributor
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
June 26, 2008
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
Author: GLG Expert Contributor
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 758

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773